UY31346A1 - Compuestos que tienen actividad en el receptor m1 y sus usos en medicina - Google Patents

Compuestos que tienen actividad en el receptor m1 y sus usos en medicina

Info

Publication number
UY31346A1
UY31346A1 UY31346A UY31346A UY31346A1 UY 31346 A1 UY31346 A1 UY 31346A1 UY 31346 A UY31346 A UY 31346A UY 31346 A UY31346 A UY 31346A UY 31346 A1 UY31346 A1 UY 31346A1
Authority
UY
Uruguay
Prior art keywords
compounds
medicine
receiver
activity
medicaments
Prior art date
Application number
UY31346A
Other languages
English (en)
Inventor
Graeme Irvine Stevenson
Dale James Johnson
Vincenzo Garzya
Paul Adrian Wyman
David Gwyn Cooper
Dr Ian Thomson Forbes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40029139&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31346(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0718419A external-priority patent/GB0718419D0/en
Priority claimed from GB0814902A external-priority patent/GB0814902D0/en
Application filed filed Critical
Publication of UY31346A1 publication Critical patent/UY31346A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan compuestos de fórmula (I) o una sal de los mismos: donde R4, R5, R6, Q, A, Y y R son como se han definido en la descripción. Se describen usos de los compuestos como medicamentos y en la fabricación de medicamentos para tratar trastornos psicóticos, alteraciones cognitivas y enfermedad de Alzheimer. La invención también describe composiciones farmacéuticas que comprenden los compuestos.
UY31346A 2007-09-20 2008-09-18 Compuestos que tienen actividad en el receptor m1 y sus usos en medicina UY31346A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0718419A GB0718419D0 (en) 2007-09-20 2007-09-20 Compounds
GB0814902A GB0814902D0 (en) 2008-08-14 2008-08-14 Compounds

Publications (1)

Publication Number Publication Date
UY31346A1 true UY31346A1 (es) 2009-04-30

Family

ID=40029139

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31346A UY31346A1 (es) 2007-09-20 2008-09-18 Compuestos que tienen actividad en el receptor m1 y sus usos en medicina

Country Status (9)

Country Link
US (1) US8299257B2 (es)
EP (1) EP2194983A1 (es)
JP (1) JP2010539218A (es)
AR (1) AR068480A1 (es)
CL (1) CL2008002808A1 (es)
PE (1) PE20091194A1 (es)
TW (1) TW200930367A (es)
UY (1) UY31346A1 (es)
WO (1) WO2009037296A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
FR2909090B1 (fr) * 2006-11-23 2009-01-09 Sanofi Aventis Sa Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique.
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
DK2148873T3 (da) * 2007-04-23 2012-11-26 Janssen Pharmaceutica Nv 4-alkoxypyridazinderivater som hurtigt dissocierende dopamin 2- receptorantagonister
AU2008240729B2 (en) * 2007-04-23 2012-08-23 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
EP2148872A1 (en) * 2007-04-23 2010-02-03 Janssen Pharmaceutica, N.V. Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
EP2194982A1 (en) * 2007-09-20 2010-06-16 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
ES2398625T3 (es) * 2008-07-03 2013-03-20 Janssen Pharmaceutica N.V. 6-(1-Piperazinil)-piritazinas sustituidas como antagonistas de receptores 5-HT6
ES2622161T3 (es) * 2008-07-31 2017-07-05 Janssen Pharmaceutica, N.V. Piridinas sustituidas con piperazin-1-il-trifluorometilo como antagonistas del receptor de la dopamina 2 de disociación rápida
TWI841671B (zh) 2019-01-24 2024-05-11 日商第一三共股份有限公司 具有取代基之脲化合物
CN112812782B (zh) * 2021-01-21 2023-09-29 西安瑞联新材料股份有限公司 一种环己烷类苯并噁唑液晶化合物、制备方法及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0786997A4 (en) * 1994-10-27 1998-03-11 Merck & Co Inc MUSCARINE ANAGONISTS
AU7478396A (en) * 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine agonists
WO1999032481A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
KR100809569B1 (ko) * 2001-10-02 2008-03-04 아카디아 파마슈티칼스 인코포레이티드 무스카린 제제로서 벤즈이미다졸리디논 유도체
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
US8288413B2 (en) * 2005-09-30 2012-10-16 Glaxo Group Limited Benzimidazolones which have activity at M1 receptor
GB0605786D0 (en) 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
EP2194982A1 (en) * 2007-09-20 2010-06-16 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine

Also Published As

Publication number Publication date
JP2010539218A (ja) 2010-12-16
AR068480A1 (es) 2009-11-18
TW200930367A (en) 2009-07-16
US8299257B2 (en) 2012-10-30
US20100210687A1 (en) 2010-08-19
EP2194983A1 (en) 2010-06-16
WO2009037296A1 (en) 2009-03-26
CL2008002808A1 (es) 2010-01-15
PE20091194A1 (es) 2009-09-05

Similar Documents

Publication Publication Date Title
UY31346A1 (es) Compuestos que tienen actividad en el receptor m1 y sus usos en medicina
EA200901373A1 (ru) Аминогетероциклические соединения
UY31405A1 (es) "piperidino-dihidrotienopirimidas sustituidas"
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
CY1121781T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης της ρασαγιλινης και χρησεις αυτων
UY32391A (es) Compuestos amino-heterocíclicos
DOP2006000141A (es) Derivados de oxindol
SV2006002055A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos ref. pc32054a
MA32898B1 (fr) Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
UY30282A1 (es) Compuestos quimicos
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
GT200500307A (es) Compuestos quimicos
ATE523495T1 (de) Substituierte pyrazolinverbindungen, deren herstellung und verwendung als medikamente
ECSP066734A (es) Derivados de ácido 7-fenilamino-4-quinolona-3-carboxílico, métodos para su producción y su uso como medicamentos
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
CR10314A (es) Compuestos que tienen actividad en el receptor m 1 y sus usos en medicina
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
UY30641A1 (es) Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
DK1751097T3 (da) Substituerede N-aryl-benzamider og relaterede sammensætninger til behandling af amyloid-sygdomme og synukleinopatier
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.